Trials / Terminated
TerminatedNCT02795325
A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1 study of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1) to determine the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics (PD) effects of DCR-PH1 administered via-intravenous infusion (IV)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DCR-PH1 | IV infusion of DCR-PH1 |
| OTHER | Placebo |
Timeline
- Start date
- 2016-05-13
- Primary completion
- 2016-10-14
- Completion
- 2016-10-14
- First posted
- 2016-06-10
- Last updated
- 2024-07-11
Locations
2 sites across 2 countries: Germany, Netherlands
Source: ClinicalTrials.gov record NCT02795325. Inclusion in this directory is not an endorsement.